Once-daily oral ICP-332, a selective tyrosine kinase 2 inhibitor, led to large reductions in Eczema Area and Severity Index scores at week 4 and significantly higher EASI-75 response rates than placebo in adults with moderate to severe atopic dermatitis, with most treatment-emergent adverse events being mild or moderate and no serious adverse events reported. These phase 2 data suggest a favorable safety and efficacy profile supporting further phase 3 evaluation of ICP-332 as a potential systemic therapy for atopic dermatitis.

Source: JAMA Dermatology